唑来膦酸降低髋部骨折术后临床骨折风险不受治疗前骨密度影响
该研究对HORIZON复发性骨折试验进行事后分析,评估唑来膦酸在低创伤髋部骨折手术修复后降低新发临床骨折风险是否受治疗前股骨颈和全髋骨密度影响。结果显示,无论骨密度作为连续变量还是以T值-2.5为界二分,基线骨密度均未修饰唑来膦酸的抗骨折疗效(交互P值均>0.20)。结论认为髋部骨折术后处方唑来膦酸无需考虑治疗前骨密度。
要点
- 唑来膦酸降低髋部骨折术后新发临床骨折风险不受治疗前股骨颈或全髋骨密度影响。
- 股骨颈骨密度T值高于和低于-2.5的患者中,唑来膦酸相对风险分别为0.60和0.67(交互P=0.95)。
- 全髋骨密度T值高于和低于-2.5的患者中,唑来膦酸相对风险分别为0.72和0.57(交互P=0.41)。
核心结论
- 唑来膦酸在低创伤髋部骨折手术修复后降低后续临床骨折风险,且该疗效不受治疗前股骨颈和全髋骨密度影响。
研究设计与样本
- 对HORIZON复发性骨折试验进行事后分析,将股骨颈和全髋骨密度分别作为连续变量和以T值-2.5为界的二分变量建模。
主要发现
- 基线股骨颈和全髋骨密度作为连续或二分变量时,均无证据修饰唑来膦酸的抗骨折疗效(交互P值均>0.20)。
- 股骨颈骨密度T值高于和低于-2.5的患者中,唑来膦酸相对风险分别为0.60和0.67(交互P=0.95)。
- 全髋骨密度T值高于和低于-2.5的患者中,唑来膦酸相对风险分别为0.72和0.57(交互P=0.41)。
关键数值与推荐
- 股骨颈骨密度T值高于和低于-2.5的患者中,唑来膦酸相对风险分别为0.60和0.67(交互P=0.95)。
- 全髋骨密度T值高于和低于-2.5的患者中,唑来膦酸相对风险分别为0.72和0.57(交互P=0.41)。
- 基线骨密度作为连续或二分变量分析时,交互P值均>0.20。
临床怎么用
- 髋部骨折手术修复后处方唑来膦酸以降低后续骨折风险时,无需依据治疗前股骨颈或全髋骨密度进行筛选。
局限性
- 本研究为HORIZON复发性骨折试验的事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In patients with surgical repair of a low-trauma hip fracture, zoledronic acid (ZA) reduced the risk of subsequent fractures regardless of pretreatment femoral neck and total hip bone mineral density (BMD). INTRODUCTION: Zoledronic acid reduces the risk of subsequent fractures after repair of a hip fracture. It is still unclear whether the benefits in fracture reduction with ZA depend upon hip bone mineral density at the time of fracture. METHODS: We preformed additional post hoc analyses of data from the HORIZON Recurrent Fracture Trial to determine if ZA treatment reduced the risk of new clinical fractures regardless of pretreatment BMD. We modeled femoral neck and total hip BMD as both continuous and dichotomous variables (BMD T-score above and below -2.5). RESULTS: There are no evidence that baseline femoral neck and total hip BMD modified the anti-fracture efficacy of ZA when pretreatment BMD was analyzed as a continuous or a dichotomous variable (interaction p-values > 0.20). The clinical fracture efficacy of ZA was similar among patients with pretreatment femoral neck BMD values above and below -2.5 (relative hazards = 0.60 and 0.67, respectively, interaction p-value = 0.95). A similar result was obtained using pretreatment total hip BMD values (relative hazards = 0.72 and 0.57, respectively, interaction p-value = 0.41). CONCLUSION: There data should provide more comfort in prescribing ZA after surgical repair of a hip fracture, regardless of pretreatment BMD.
引用
- Lyles KW, Bauer DC, Colon-Emeric CS, et al. Zoledronic acid reduces the rate of clinical fractures after surgical repair of a hip fracture regardless of the Pretreatment bone mineral density. Osteoporos Int. 2021. PMID: 33903925. doi:10.1007/s00198-021-05923-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。